Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mouse gut metagenome

ABSTRACT: Mouse gut metagenome of HFD mice after receiving Ganoderma lucidum treated fecal transplant

PROVIDER: PRJNA284556 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR2034720.fastq.gz	Fastqsanger.gz
	SRR2034730.fastq.gz	Fastqsanger.gz
	SRR2034740.fastq.gz	Fastqsanger.gz
	SRR2034721.fastq.gz	Fastqsanger.gz
	SRR2034731.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

mouse gut metagenome

Project description:Mouse gut metagenome after HFD and Ganoderma lucidum

| PRJNA282780 | ENA

Adenosine-rich extract of Ganoderma lucidum: a safe and effective lipid-lowering substance via regulating expression and modulation of PPAR signaling pathway

Project description:Ganoderma lucidum is a traditional Chinese medicine with a variety of active compounds and possessing adequate lipid-lowering and anti-atherosclerotic effects. However, its main active components and potential mechanisms still remain unclear. Here, we evaluated the anti-hyperlipidemic effect of the adenosine extract from Ganoderma lucidum (AEGL) in high-fat-diet (HFD)-induced hyperlipidemic ApoE-/- mice and explored the underlying biological mechanism by multi-omics analysis. Treatment with AEGL for 8 weeks significantly decreased the serum levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-c) by 45.59%, 41.22%, and 39.02%, respectively, as well as reduced liver TC and TG by 44.15% and 76.23%, compared with the HFD-only group. We also observed significant amelioration of hepatic steatosis without liver and kidney damage after AEGL treatment. Regulating the expression and acetylation/crotonylation of proteins involved in the PPAR signaling pathway may be one of the potential mechanisms involved in the observed lipid-lowering effects of AEGL.

2023-03-11 | PXD036478 | Pride

miRNA profiling of Hepa1-6-bearing mouse model

Project description:the Hepa1-6-bearing C57 BL/6 mouse model was utilized to explore the therapeutic efficacy of Ganoderma lucidum extract (GLE), documenting that it could effectively inhibit tumor growth. Furthermore, the microRNA (miRNA) profiles of GLE-treated and untreated mice were detected, and 25 differential expressed (DE) miRNAs were determined, including 24 up-expressed and one down-expressed miRNAs., documenting that it could effectively inhibit tumor growth. Furthermore, the microRNA (miRNA profiles of GLE-treated and untreated mice were detected, and 25 differential expressed (DE miRNAs were determined, including 24 up-expressed and one down-expressed miRNAs.

2019-12-29 | GSE142692 | GEO

Transcriptional profiling of Hepa1-6-bearing mouse model

Project description:Hepa1-6-bearing C57BL/6 mouse model was established to evaluate the therapeutic efficacy of Ganoderma lucidum extract (GLE) in HCC. The GLE treated and untreated mice were used for transcriptioanl profiles detection, and 126 differentially expressed lncRNAs and 558 DE mRNAs were identified, respectively. The bioinformatics analysis shows that the GLE could suppress the growth and proliferation of HCC by PI3K/Akt/mTOR and MAPK signaling pathway, and also could induce apoptosis of tumor cell by mitochondrial and death receptor pathway.

2018-08-02 | GSE117503 | GEO

Project description:Ganoderma lucidum polysaccharides on human fecal

| PRJNA987189 | ENA

Fecal Transplant from Roux-Y-Gastric-Bypass rat model into a diet induced obesity rat model

Project description:Investigating alterations the intestinal microbiome in a diet induced obesity (DIO) rat model after fecal transplant from rats, which underwent Roux-Y-Gastric-Bypass surgery (RYGB). The microbiomes of the RYGB-donor rats, the DIO rats, and DIO rats after receiving the fecal transplant from the RYGB rats. As controls lean rats as well as lean, RYGB and DIO rats after antibiotics treatment were used.

2022-08-12 | PXD026606 | Pride

Mouse Fecal Microbiome

Project description:Raw reads from mouse microbiomes receiving fecal virome transplant

| PRJNA930016 | ENA

Gut Dysbiosis Impacts Brain Metastasis Outgrowth and Immune Response Dynamics

Project description:We used 16S V3/V4 region amplification to evaluate the composition of bacteria species in mouse fecal pellets after vehicle or ABX treatment and before and after fecal matter transplant.

2025-02-05 | GSE270809 | GEO

mouse gut metagenome

Project description:Characterized the fecal microbiota of mice fed different dietary protein diets and HFD

| PRJDB7246 | ENA

Transcriptome analysis reveals LZ-8 triggers antiviral innate immunity in mouse T lymphocytes [RNASeq1]

Project description:Ganoderma lucidum is a traditional medicinal herb that has commonly been used for treating virus infections. Protein LZ-8 comes from Ganoderma lucidum and has immunomodulatory and antiviral activities. However, the potential molecular antiviral mechanism of LZ-8 is still unclear. In this study transcriptome analysis was used to gain a deeper insight into the antiviral effects of LZ-8 on T lymphocytes. Deseq analysis showed that 2724 genes were upregulated and 3314 genes were downregulated after LZ-8 treatment for 5 hours. GO enrichment analysis showed that the upregulated genes were significantly enriched in biological processes including defense response to virus, ribosome biosynthesis, RNA processing, etc. The downregulated genes were significantly enriched in biological processes including cell cycle, signal transduction, etc. Pathway enrichment analysis indicated that NF- κB signaling pathway was closely related to LZ-8. RT-qPCR confirmed that inhibition of the NF-κB signaling pathway reversed the elevated transcriptional level of antiviral genes including Ifit1, Isg15, Mx1, Ifit3, and Ifih1 in T lymphocytes triggered by LZ-8. In a word, our study demonstrated that LZ-8 triggered the antiviral innate immunity of T lymphocytes through the NF-κB signaling pathway.

2025-03-28 | GSE199519 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data